Case report · 2013
Review articlePublished 26 Jul 2016
Novel formulations and routes of administration for opioids in the treatment of breakthrough pain
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The interest for assessment and treatment of breakthrough pain (BTP) has been increasing, probably due to a growing attentiveness towards the problems associated with BTP, but also encouraged by the development of novel pharmaceutical formulations specially intended for the treatment of BTP. BTP can be described as ‘an episodic increase in pain intensity over a stable and adequately managed baseline pain’. BTP is a heterogeneous condition, and the most optimal treatment is influenced by a number of different pain-related factors, including the etiology of the pain (cancer or noncancer pain), the pathophysiology of the pain (nociceptive or neuropathic), the characteristics of the pain (type, frequency, and duration). Furthermore, it will depend on various patient-related conditions, such as stage of disease, performance status, compliance and the acceptability of different interventions. Treatment of BTP should be individualized to fit the special needs of the single individual patient. The optimal opioid formulation for the treatment of BTP possesses a pharmacological profile that closely mirrors the intensity–time profile of the BTP episode. Thus, a short onset of action (to relieve pain as quickly as possible) and a relatively short duration of action (to prevent side effects) are preferable. Factors that influence the pharmacological profile of a drug are the physicochemical, pharmaco-kinetic and -dynamic properties of the drug substance, the pharmaceutical formulation and the route of administration. To date, only few formulations specially designed and intended for the treatment of BTP are available. However, many are currently under development and clinical assessment, and some of these are very close to reaching the market.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 13 Sep 2017
Opioid Tolerance Leveling: A novel strategy to manage pain safely and effectively in hospitalized non-surgical patients
Commentary · Apr 2010
Embeda: morphine sulfate extended-release capsules with sequestered naltrexone, a novel opioid formulation for the treatment of chronic pain
Review article · 2015
Routes of Opioid Abuse and its Novel Deterrent Formulations
Review article · 15 Jan 2021
Ketamine Versus Standard Opioid Treatment for Acute Pain in the Emergency Department: Systematic Review and Meta-analysis
More from this journal
The newest in Clinical Practice.
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 28 Mar 2025
Using
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Lona Louring Christrup”
- BylineArticles whose byline prints “Lena Lundorff”
- BylineArticles whose byline prints “Mads Werner”
